Tiny study aims to find best way to check blood thinner levels in kids

NCT ID NCT07365670

Not yet recruiting Knowledge-focused Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 22 children with congenital heart disease who are getting a blood thinner called heparin. Doctors want to see if taking blood from a central line (a special IV) gives the same results as taking blood from an artery. They will compare three different ways of drawing blood to find the most accurate method. The goal is to make monitoring safer and reduce the chance of bleeding or clots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: unfractionated heparin
What this could lead to: If successful, this could identify a simpler, more reliable way to monitor heparin levels in children, potentially reducing bleeding or clotting risks.
What could go wrong: This is a small, early-stage study with only 22 participants, so results may not apply to all children. It focuses on measurement methods, not a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-XA ACTIVITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital heart disease thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-XA ACTIVITY CONGENITAL HEART DISEASE UNFRACTIONATED HEPARIN

More trials for these conditions

Other studies related to the condition(s) this trial covers.